effective in inducing tolerance. A large-scale, clinical trial of feeding bovine retinal proteins to patients with posterior uveitis at NIH is due to report in the near future. However, oral administration requires huge amounts of purified protein, which is unlikely to be economically viable on a large scale. Furthermore, using proteins derived from the neural tissue of cows in the UK is unlikely to be acceptable to patients for the foreseeable future. However, recombinant anti gens can be made and the smaller but equally effective doses required for nasal tolerisation would seem to be relevant and certainly hold promise for the future. Intriguingly, in experimental models, it has been shown that tolerance may be induced by giving the antigen in tear drops at an equivalent dose to the nasal route , 11 and it may well be that we will be able to offer our patients therapy in the form of eye drops before too long.
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